Torrent Pharmaceuticals Limited has once again expanded its recall of Losartan potassium tablets and Losartan potassium/hydrochlorothiazide tablets, the Food and Drug Administration announced Thursday.
The company has added an additional 36 lots of Losartan potassium tablets and 68 lots of Losartan potassium/hydrochlorothiazide tablets.
The recall is due once again to an impurity called N-Methylnitrosobutric acid or NMBA.
The recalled lots have more NMBA than what is acceptable for daily intake set by the FDA.
Consumers with medical questions connected to the recall are being instructed to call Torrent Pharmaceuticals at 1-800-912-9561 or email Medinfo.Torrent@apcerls.com.
For more information, including the complete list of batch numbers included with the recall’s expansion, click here.
© 2019 Cox Media Group.